Earnings summaries and quarterly performance for FIBROGEN.
Executive leadership at FIBROGEN.
Board of directors at FIBROGEN.
Research analysts who have asked questions during FIBROGEN earnings calls.
AH
Andy Hsieh
William Blair & Company
3 questions for FGEN
Also covers: ALT, BYSI, CRDF +8 more
Khalil Fenina
Goldman Sachs
2 questions for FGEN
Also covers: PTCT
Matthew Keller
H.C. Wainwright & Co., LLC
2 questions for FGEN
Also covers: ACXP, ITRM
TH
Tsan-Yu Hsieh
William Blair & Company
1 question for FGEN
Also covers: AVIR, CRDF, EXEL +6 more
Recent press releases and 8-K filings for FGEN.
FibroGen Rebrands as Kyntra Bio, Shifts Strategic Focus
FGEN
New Projects/Investments
Guidance Update
- FibroGen, Inc. has rebranded as Kyntra Bio, effective January 7, 2026, with its common stock beginning to trade under the new Nasdaq symbol "KYNB" on January 8, 2026.
- The rebranding reflects a sharpened focus on novel therapies in oncology and rare disease, with key assets including FG-3246, FG-3180, and roxadustat. The company has also extended its cash runway into 2028.
- Upcoming milestones include topline results from an investigator-sponsored Phase 1b/2 study of FG-3246 in Q1 2026 and interim results from a Phase 2 monotherapy trial in the second half of 2026.
- Roxadustat received Orphan Drug Designation from the FDA for myelodysplastic syndromes, and a pivotal Phase 3 clinical trial protocol has been submitted.
4 days ago
FibroGen's Roxadustat Receives FDA Orphan Drug Designation for Myelodysplastic Syndromes
FGEN
Product Launch
New Projects/Investments
- FibroGen's roxadustat has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of myelodysplastic syndromes (MDS).
- This designation provides potential benefits, including seven years of market exclusivity in the U.S. following drug approval, exemption from certain FDA fees, and financial incentives for qualified clinical development.
- The company is on track to file the Phase 3 protocol for roxadustat in this patient population with the FDA in the fourth quarter of 2025.
- Roxadustat, an oral medication, demonstrated an improvement in transfusion-independence in a subset of patients with high transfusion burden in a post-hoc analysis from the Phase 3 MATTERHORN trial.
Dec 15, 2025, 12:00 PM
FibroGen Reports Q3 2025 Financial Results and Pipeline Updates
FGEN
Earnings
M&A
New Projects/Investments
- FibroGen completed the sale of FibroGen China to AstraZeneca for approximately $220 million in Q3 2025, which included an enterprise value of $85 million and approximately $135 million of net cash held in China.
- This transaction enabled the company to repay its term loan to Morgan Stanley Tactical Value and extend its cash runway into 2028.
- FibroGen initiated a Phase 2 monotherapy trial for FG-3246 and FG-3180 in metastatic castration-resistant prostate cancer (mCRPC), with interim results expected in 2H 2026.
- The company plans to submit the Phase 3 protocol in Q4 2025 for roxadustat in anemia of low-risk myelodysplastic syndromes (LR-MDS), with a potential Phase 3 initiation in 2026.
Nov 10, 2025, 10:00 PM
FibroGen Reports Q3 2025 Financials and Provides Business Update
FGEN
Earnings
Guidance Update
New Projects/Investments
- FibroGen reported $1.1 million in total revenue for Q3 2025 and a net loss from continuing operations of $13.1 million, or $3.25 per basic and diluted share. Total operating costs and expenses significantly decreased by 86% year-over-year to $6.5 million.
- The sale of FibroGen China in August 2025 for approximately $220 million extended the company's cash runway into 2028 and enabled the payoff of a $80.9 million term loan.
- The company reiterated its full-year 2025 total revenue guidance of $6 million to $8 million and updated its total operating costs and expenses guidance to $50 million to $60 million, representing a 70% reduction from full-year 2024 at the midpoint.
- FibroGen initiated a Phase 2 monotherapy trial for FG3246 in Q3 2025, with top-line results from an investigator-sponsored trial expected in Q1 2026 and interim Phase 2 results in H2 2026. For Roxadustat, the Phase 3 trial protocol for lower-risk myelodysplastic syndromes is on track for submission in Q4 2025, with a decision on independent development or partnering expected by Q2 2026.
Nov 10, 2025, 10:00 PM
FibroGen Reports Q3 2025 Financial Results and Business Updates
FGEN
Earnings
M&A
New Projects/Investments
- FibroGen reported total revenue from continuing operations of $1.1 million and a net loss from continuing operations of $13.1 million for the third quarter of 2025.
- The company completed the sale of FibroGen China to AstraZeneca for approximately $220 million, which included $135 million in net cash, extending its cash runway into 2028.
- Key clinical developments include the initiation of the Phase 2 monotherapy trial of FG-3246 and an agreement with the FDA on the pivotal Phase 3 trial design for roxadustat in LR-MDS, with protocol submission anticipated in Q4 2025.
Nov 10, 2025, 9:05 PM
FibroGen Reports Q3 2025 Financial Results and Business Update
FGEN
Earnings
M&A
New Projects/Investments
- FibroGen reported total revenue from continuing operations of $1.1 million and a net loss from continuing operations of $13.1 million for the third quarter of 2025.
- The company completed the sale of FibroGen China to AstraZeneca for approximately $220 million, which helped simplify its capital structure.
- As of September 30, 2025, FibroGen held $121.1 million in cash, cash equivalents, investments, and accounts receivable, extending its cash runway into 2028.
- Key clinical developments include the initiation of the Phase 2 monotherapy trial of FG-3246 for metastatic castration-resistant prostate cancer and agreement with the FDA on design elements for the pivotal Phase 3 trial for roxadustat in lower-risk myelodysplastic syndromes.
- Upcoming milestones include topline results for an investigator-sponsored FG-3246 study in 1Q 2026 and the anticipated Phase 3 protocol submission for roxadustat in 4Q 2025.
Nov 10, 2025, 9:02 PM
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
FGEN
Earnings
Guidance Update
New Projects/Investments
- For the nine months ended September 30, 2025, FibroBiologics reported a net loss of approximately $15.4 million and held cash and cash equivalents of approximately $4.9 million.
- The company is advancing preparations for manufacturing CYWC628 for a Phase 1/2 clinical trial in diabetic foot ulcers (DFU) patients, with trial initiation in Australia planned for the first quarter of 2026.
- FibroBiologics is also preparing to submit Investigational New Drug (IND) applications for CYPS317 for psoriasis and CYMS101 for multiple sclerosis.
- To optimize resource allocation, the company implemented cost-efficient measures to reduce operating expenses and prioritize near-term pipeline goals.
Oct 31, 2025, 8:30 PM
FibroGen completes sale of China subsidiary to AstraZeneca
FGEN
M&A
Guidance Update
- FibroGen completed the sale of its China subsidiary to AstraZeneca for approximately $220 million, consisting of $85 million in enterprise value and approximately $135 million in net cash.
- This transaction substantially strengthens FibroGen's financial position, extending its cash runway into 2028, and allowed for the repayment of an approximately $81 million term loan to Morgan Stanley Tactical Value.
- The company remains on track to initiate the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) in 3Q 2025 and intends to file the Phase 3 protocol for roxadustat in anemia associated with lower-risk MDS in 4Q 2025.
Sep 2, 2025, 11:09 AM
Quarterly earnings call transcripts for FIBROGEN.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more